

TRISTEL plc
("Tristel" or the "Company")

Confirmation of Investor presentations

Capital Markets Day & Shareholder Open Day

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, confirms it will host two investor presentations on consecutive days next week, Tuesday 29 July 2025 and Wednesday 30 of July 2025.

Both sessions will feature the same presentations delivered by Matt Sassone, CEO, and Tiffany Woolwine, MBA, BS, RDMS one of Tristel's US customers from Orlando Health. Tiffany will focus on the benefits of Tristel's approach and on her experience using Tristel ULT.

The meetings will also provide Investors and Shareholders with the opportunity to meet members of the Board, the Senior Leadership Team and familiarise themselves with the Company's products. This will be facilitated through various stations, where Senior Management will deliver brief presentations on the following topics: Geographic expansion, US market, New Products, 3T digital offering, Clinical validation.

There will also be a trading update for the year ended 30 June 2025 which will be announced at 7am on Tuesday 29 July 2025, ahead of the Capital Markets Day.

Details of the two events are detailed below:

Capital Markets Day

The Capital Markets Day will be hosted in the City of London on Tuesday 29 July 2025. The event will commence at 14:30pm BST and welcomes Institutional Investors and Analysts. For more information and to register please contact Walbrook PR via tristel@walbrookpr.com.

Shareholder Open Day

The Shareholder Open Day will be hosted at the Company's headquarters in Snailwell, Cambridgeshire on Wednesday 30 July 2025. Shareholders are welcome from 12:00pm BST. Availability is limited so please contact Walbrook PR via tristel@walbrookpr.com or call 020 7933 8780 to reserve an entry ticket.

As a reminder, for those that are unable to make the above presentations in person, a recording will be made available on the Company's website, shortly after the event, here: <https://tristelgroup.com/invest/webinars-presentations/>.

No new material information regarding current trading or outlook will be disclosed during the day.

For further information please contact:

Tristel plc
Matt Sassone, Chief Executive Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd
Paul McManus / Lianne Applegarth / Alice Woodings

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893/ 07584 391 303/ 07407 804 654

Cavendish Capital Markets Ltd
Geoff Nash / Callum Davidson/Trisyia Jamaludin (Corporate Finance)
Sunila de Silva (Corporate Broking) / Louise Talbot (Sales)

Tel: 020 7220 0500



About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, a more sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 270 people across 16 subsidiaries selling into 40+ countries. The Company targets annual revenue growth of between 10% and 15% and an EBITDA margin of at least 25% and the business is profitable, with no debt and has a progressive dividend policy.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCRJMTMTMTBMA